Tellgen(SZ:300642) Ge Long Hui A P P·2025-10-23 12:26Core Viewpoint - The company has signed investment agreements with multiple parties to acquire a stake in Weihe Bio, focusing on the development of innovative treatments for tumors and autoimmune diseases, aligning with its long-term strategic goals in the healthcare sector [1] Group 1: Investment Details - The company will invest RMB 68 million to subscribe for an increase in registered capital of RMB 175,992 [1] - After the investment, the company will hold a 9.2141% equity stake in Weihe Bio [1] Group 2: Business Focus - Weihe Bio specializes in the development of new treatments for tumor immunity and autoimmune diseases [1] - The company possesses a multi-specific antibody drug design platform [1] Group 3: Strategic Alignment - This investment is a key move for the company to implement its full-chain layout in the autoimmune disease field, covering diagnosis, treatment, and monitoring [1] - The investment aligns with the company's long-term strategy to leverage diagnostic technology advantages to extend into the treatment field, aiming to build comprehensive life and health service capabilities [1]